Go Pro
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel
LON:PXS

Provexis Interim Earnings Report

GBX 1.14 +0.09 (+8.38%)
As of 07:19 AM Eastern
ProfileEarnings History

Provexis EPS Results

Actual EPS
-GBX 0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Provexis Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Provexis Announcement Details

Quarter
Interim
Date
12/31/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Provexis Earnings Headlines

AIM Market Roundup: Ramsdens, Provexis, Pulsar Helium
June 24, 2026  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/news/aim-market-roundup-ramsdens-provexis-155328723.html
Provexis Secures Shareholder Support and Advances in Chinese Market
November 21, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/provexis-secures-shareholder-support-and-advances-in-chinese-market?utm_source=marketbeat.com&utm_medium=referral
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.tc pixel
September 7 at 1:00 AM  |  The Oxford Club (Ad)
AIM Market Roundup: Provexis, Geo Exploration, Sabien
November 19, 2025  |  sg.finance.yahoo.comhttps://sg.finance.yahoo.com/news/aim-market-roundup-provexis-geo-142747730.html
Provexis Faces Temporary Trading Suspension Amid Financial Reporting Delay
September 30, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/provexis-faces-temporary-trading-suspension-amid-financial-reporting-delay?utm_source=marketbeat.com&utm_medium=referral
Phase I trial finds topical PXS-6302 generally well tolerated in established skin scars
September 12, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/phase-i-trial-finds-topical-pxs-6302-generally-well-tolerated-in-established-skin-scars/ar-AA1MqHQg
See More Provexis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Provexis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Provexis and other key companies, straight to your email.

About Provexis

Provexis (LON:PXS), together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in various foods, beverages, and dietary supplement formats. It offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and heart function. The company sells its products through distributors and online channels. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.

View Provexis Profile
Earnings Tools